WFH, Sanofi and Sobi for Armenia: Unprecedented Commitment to Build the Humanitarian Aid Program
Scott Williams, VP and Head, Global Public Affairs at Sanofi, shared an honoring post on LinkedIn:
”In 2014, the World Federation of Hemophilia (WFH) put out a call to action to join them and build their Humanitarian Aid (HA) Program into a more sustainable and predictable solution. Sanofi, along with Sobi, responded with an unprecedented commitment – to provide 1 billion IUs of factor therapy over 10 years. This commitment drove other companies to collaborate with the WFH HA Program and together, we empowered the WFH to provide treatment not only for life-saving surgeries but also for acute bleeds and prophylaxis in children.
I have just returned from a Humanitarian Aid visit with the World Federation of Hemophilia to Armenia. It is with humility that I share a look into 5 extraordinary days together.
It was so impactful to see the before and after progress that’s been made over the past 10+ years in Armenia. We saw a strong hemophilia treatment center and integrated multi-disciplinary care team, access to factor therapy, ability to have prophylaxis treatment at home, impactful local patient organization (NMO), and more. Meeting and hearing the stories of patients and families whose lives have been forever transformed truly puts the “human” in the humanitarian program. It is a powerful reminder of the good that can be achieved when we work together with a shared purpose.
At Sanofi, we are working as a committed industry partner with stakeholders across the bleeding disorders community to drive forward comprehensive, patient-centric solutions that go Beyond the Bleed to meaningfully advance the care paradigm. Envisioning a future beyond the bleed lies at the heart of our mission.
I will never be the same after the visit to Armenia with the WFH. The tears, hope, smiles, determination, and perseverance of children and family members living with hemophilia ensured that I will continue to be a deeply committed Rare Ambassador.”
More encouraging stories featured in Hemostasis Today.
-
Mar 20, 2026, 17:47Julie Rayes: Commenting on a Seminal NEJM Study Solving the Mystery of VITT
-
Mar 20, 2026, 17:45William Tembo: Advancing Stroke Care by Validating Acute Ischemic Treatment
-
Mar 20, 2026, 17:37Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
-
Mar 20, 2026, 17:35Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
-
Mar 20, 2026, 17:17Angelo Cascio Rizzo: CTA-Based Plaque RADS Improves Risk Stratification in ESUS
-
Mar 20, 2026, 17:09Clinical Practice Guidelines for Platelet Transfusion in Non-Surgical and Non-Traumatic Settings – CEBaP
-
Mar 20, 2026, 17:07The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
-
Mar 20, 2026, 17:05Pierre Fontana: Launching the European Interuniversity Certificate in Clinical Haemostasis
-
Mar 20, 2026, 16:49Wolfgang Miesbach: A Pivotal Step Forward for Patients with von Willebrand Disease Across All Subtypes